La Jolla’s (LJPC) shares lost almost half of their value Monday, after the company pre-announced fourth quarter revenues for its drug Giapreza – …
Cowen’s Phil Nadeau looks for “rapid adoption” in La Jolla’s Giapreza’s approved wider indication to hike up blood pressure in refractory patients.
